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ABSTRACT
A prospective clinical and microbiological surveillance study was conducted during a 26-month period
to evaluate consecutive malignancy or post-bone marrow transplant patients with positive blood
cultures. The study included 859 episodes of bloodstream infection (BSI) in 719 patients. There were 6.9
BSI episodes ⁄ 1000 patient-days. Overall mortality was 25%. The median age of patients was 43 years,
with 71% of episodes occurring in patients aged > 18 years. Patients with underlying haematology
malignancies accounted for 38.2% of the episodes. An indwelling central vein catheter was present in
61% of episodes. BSI origin was unknown in 27% of episodes, associated with other sites in 49.6%, and
catheter-related in 23.4%. There were 638 concomitant infection sites, of which the most common were
pulmonary (28.4%), urinary tract (14.8%), and non-surgical skin or soft tissue (9.7%). In total, 1039
microorganisms were isolated within 48 h of the ﬁrst blood culture, of which Gram-negative bacilli
accounted for 56%. Among Klebsiella pneumoniae and Escherichia coli isolates, 37.8% and 8.9%,
respectively, produced extended-spectrum b-lactamases. High rates of ceftazidime resistance were
detected among Acinetobacter spp. (40%) and Enterobacter spp. (51.2%). E. coli and K. pneumoniae were
isolated frequently from haematology patients, and Enterobacter spp. from solid tumour patients. E. coli,
K. pneumoniae and Pseudomonas aeruginosa were isolated more often from neutropenic than from non-
neutropenic patients. Oxacillin resistance was detected in 18.7% of Staphylococcus aureus isolates. It was
concluded that continuous multidisciplinary surveillance of BSI is warranted in this high-risk group of
patients in order to develop strategies for antimicrobial resistance control and treatment of infectious
complications.
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INTRODUCTION
Bloodstream infection (BSI) caused by bacterial or
fungal pathogens remains an important cause of
morbidity and mortality in cancer patients [1–4].
The rising incidence of hospital-acquired BSI, and
the high prevalence of antimicrobial resistance
among these organisms, mean that most hospitals
have implemented local infection control surveil-
lance in order to develop intervention strategies.
The impact of this on the prevention and control
of nosocomial BSI has been well-documented
[5,6]. Considering the varying incidence of infec-
tion between institutions, associated with differ-
ent underlying diseases, medical approaches and
treatment protocols, infectious complications
should be monitored throughout the entire period
of therapy in order to assess the inﬂuence of
different factors on outcome. One approach
involves continuous surveillance of antimicrobial
susceptibility patterns as part of a programme to
control and prevent the development of resist-
ance, and subsequently to treat patients accord-
ingly [7]. The widespread use of empirical and
prolonged antibiotic therapy in cancer patients
has created great concern about the emergence of
resistant pathogens. In January 2000, the National
Cancer Institute in Rio de Janeiro, Brazil, initiated
prospective surveillance of all BSIs in order to
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advise on the adequacy of antimicrobial therapy
in the management of these severe infections, and
thus improve patient outcome. This study des-
cribes the frequencies of occurrence and antimi-
crobial susceptibility proﬁles of BSI isolates in this
single Brazilian cancer centre. The present analy-
sis was also compared with a previous retrospec-
tive cohort, which covered the period from
January 1993 to December 1994 [8].
MATERIALS AND METHODS
The study was conducted at the Hospital do Caˆncer, National
Cancer Institute, Rio de Janeiro, Brazil. This is a 206-bed
tertiary oncology care centre, including medical and surgical
intensive care and bone marrow transplantation units, which
admits c. 7860 patients annually, of whom c. 5700 (73%)
undergo surgical procedures. All consecutive malignancy or
post-bone marrow transplant in-patients who presented with
positive blood cultures (BCs) from 1 January 2000 to 28
February 2002, according to daily microbiology laboratory
reports, were included.
Blood was drawn by nursing staff. The standard protocol
required at least two blood samples for culture before or at the
moment of antibiotic initiation. If a central venous catheter
(CVC) was in place, one blood sample was obtained from the
catheter lumen, as well as from a peripheral vein whenever
feasible. Each positive BC was evaluated to determine whe-
ther, on the basis of clinical or microbiological data, it
represented true bacteraemia, fungaemia, or simply contam-
ination. For coagulase-negative staphylococci (CoNS), coryne-
bacteria other than Corynebacterium jeikeium, and other com-
mon skin contaminants, at least two separate positive BCs
obtained from different sites were required. In addition, such
BCs had to be considered as clinically signiﬁcant and antimi-
crobial therapy started.
The unit of analysis was a BSI episode, and the date of onset
was considered to be that of the ﬁrst positive BC (index BC).
The end of the episode was deﬁned as the date when the
patient became afebrile without clinical and laboratory signs of
infection, or at death if this occurred during the infectious
episode. Patients were followed for a period of 30 days after
the last positive BC. The crude mortality deﬁned the ratio of
the number of patients who died during the BSI episode to the
total number of patients with BSI. Patients could re-enter the
protocol if an interval of at least 14 days without clinical signs
of infection had elapsed since the preceding episode. All
empirical antibiotic therapy prescribed for febrile patients
followed written internal guidelines provided to all physicians
working at the hospital.
Criteria for infection deﬁnitions were adapted from those
recommended by the Centers for Disease Control [9], and were
in accordance with Sickles et al. [10]. Associated BSI episodes
were those which occurred concomitantly or close to a
clinically or laboratory-proven site of infection. Catheter-
related BSI was deﬁned as: the presence of fever with either
chills and rigors within 1 h of catheter ﬂushing or manipula-
tion, with resolution after CVC removal; the presence of
catheter exit site or subcutaneous tunnel infection; or recovery
of the same microorganism from blood and catheter tip (roll-
plate semiquantitative culture with ‡ 15 CFU) with no evi-
dence of another source for BSI. The following variables were
analysed: underlying conditions (haematology vs. solid tu-
mour); history of previous surgery (£ 30 days); presence of
neutropenia (absolute neutrophil cell count £ 1000 ⁄mm3) at the
moment of index BC; uni-microbial or poly-microbial episode
(according to the number of species isolated during the entire
BSI episode); and the presence and type of CVC.
Blood specimens were inoculated into Bactec Peds Plus
vials and Bactec Plus anaerobic or aerobic vials (Becton-
Dickinson, Sparks, MD, USA), and all cultures were processed
in a Bactec 9240 continuous-monitoring system (Becton-Dick-
inson). All negative bottles were incubated for 30 days. Isolates
from positive bottles were identiﬁed by standard methods,
with the automated Vitek System (bioMe´rieux, Lyon,
France) [11,12]. Kirby–Bauer disk diffusion and Etests were
performed according to the isolate. Isolates with a ceftazidime
MIC ‡ 2 mg ⁄L were considered to be resistant and to be
presumptive extended-spectrum b-lactamase (ESBL) or
AmpC-type b-lactamase producers. Disk approximation tests
with ceftazidime, ceftriaxone and cefepime plus amoxycil-
lin + clavulanate disks were used to conﬁrm the presence of an
ESBL in such isolates. Positive BCs for yeast were processed
further in the mycology laboratory. Yeasts were identiﬁed on
the basis of morphology and biochemical characteristics (API
20C; bioMe´rieux, Marcy l’Etoile, France). Non-yeast fungi were
identiﬁed on the basis of morphology.
All data were analysed with EpiInfo software (Centers for
Disease Control, Atlanta, GA, USA). For calculation purposes,
pathogens with intermediate antibiotic susceptibilities were
considered resistant. Categorical variables were compared
using the chi-square test or Fisher exact test, as appropriate,
and the Student’s test was used for continuous variables;
p values £ 0.05 (two-sided) were considered to be statistically
signiﬁcant.
RESULTS
The study comprised 859 episodes of BSI in
719 patients (421 males and 298 females). The
median age was 43 years (range, 1–94 years), and
612 (71.2%) episodes occurred in patients aged
> 18 years. There were 6.9 BSI episodes ⁄ 1000
patient-days (5.1 episodes ⁄ 100 admissions). In
502 (58.4%) episodes, patients had their index
BC 48 h after admission.
There were 3718 blood samples drawn, inclu-
ding follow-up cultures, during the 26-month
study period. Of these, 422 (11.3%) were positive
with what were considered to be contaminant
organisms, while 1843 (49.5%) represented true
bacteraemia or fungaemia. The crude mortality
rate during the study period was 25.1%.
BSI episodes were classiﬁed as being of un-
known origin (n ¼ 232; 27.0%), catheter-related
(n ¼ 201; 23.4%), or associated with other sites
(n ¼ 426; 49.6%). There were 638 concomitantly
infected sites that were documented clinically or
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by the laboratory. The most common associated
diagnosis was pulmonary infection (28.4%), fol-
lowed by urinary tract infection (14.8%), non-
surgical skin or soft tissue infection (9.7%) and
surgical site infection (8.5%).
BSI episodes occurred in patients with under-
lying haematological malignancies (n ¼ 351;
41%), of whom 134 (38.2%) had acute leukaemia
(40 in relapse) and 133 had lymphoma (69.0%
with advanced disease). BSI episodes occurred in
non-neutropenic patients (n ¼ 568; 66%), in pa-
tients subjected to an operative procedure
(n ¼ 217), and in the ﬁrst 100 days post-bone
marrow transplantation (n ¼ 99).
In total, 1036 microorganisms were isolated
within 48 h of the index BC. Most (56%; n ¼ 583)
were Gram-negative organisms, 32% (n ¼ 328)
were Gram-positive organisms, 10% (n ¼ 104)
were fungi, and 2% (n ¼ 21) were other organ-
isms. The most prevalent isolates were Escherichia
coli (11%) and CoNS (10.8%), among which
Staphylococcus epidermidis predominated (73.2%)
(Table 1). Enterococcus faecalis comprised most
(85.2%) of the enterococci. Among Candida iso-
lates, 79.0% were non-albicans Candida spp.,
mainly Candida tropicalis and Candida parapsilosis.
Oxacillin resistance was detected in 18.7% and
77.5% of Staphylococcus aureus and S. epidermidis
isolates, respectively. Among viridans strepto-
cocci, 36.6% were penicillin-resistant. No vanco-
mycin-resistant Gram-positive cocci were
identiﬁed.
Antibiotic resistance among the seven most
prevalent aerobic Gram-negative bacilli (AGNB)
is shown in Table 2. Approximately 10% (n ¼ 12)
of E. coli isolates were ceftazidime-resistant, and
most (n ¼ 11) were ESBL-producing strains. All 28
(37.8%) ceftazidime-resistant Klebsiella pneumoniae
isolates had an ESBL phenotype. Resistance rates
of Pseudomonas aeruginosa isolates were similar for
amikacin (22.5%), ceftazidime (23.9%), cefepime
(28.2%) and piperacillin + tazobactam (21.1%).
Resistance to ceftazidime and piperacillin + tazo-
bactam varied from 33% to 55% in Enterobacter
cloacae and Enterobacter aerogenes isolates, which
accounted for c. 8% of all BSI isolates. Ceftazidime
resistance was identiﬁed in 50% of Citrobacter
spp., 20% of Serratia spp. isolates, 36.6% of
Acinetobacter baumannii isolate and 55.5% of Aci-
netobacter lwofﬁi isolates. Piperacillin + tazobac-
tam was the most active penicillin compound,
inhibiting 79% of Acinetobacter spp. isolates. Over-
all, imipenem remained the most active agent
against all AGNB isolated from blood.
There were more uni-microbial than poly-
microbial episodes (73.8% vs. 26.2%), and more
poly-microbial infections occurred 48 h after
admission (66.2% vs. 55.7%; p 0.06). Gram-neg-
ative isolates were observed more frequently in
poly-microbial (n ¼ 242; 60.2%) than in uni-
microbial infections (n ¼ 341; 53.8%; p 0.04).
Streptococci (11.8% vs. 5.2%; p < 0.01), E. coli
(12.8% vs. 8.2%; p 0.03) and S. aureus (10.6%
vs. 6.0%; p 0.01) were associated more frequently
with uni-microbial than poly-microbial episodes,
respectively. When compared to poly-microbial
events, uni-microbial BSI episodes were associ-
ated more frequently (p < 0.01) with an unknown
origin (78.9% vs. 21.1%), concomitant infected
sites (74.6% vs. 25.4%) and CVC-related infection
(66.2% vs. 33.8%). The predominant strains
isolated during poly-microbial events were CoNS
(12.0%), Acinetobacter spp. (9.9%), Enterobacter
spp. (8.5%), Klebsiella spp. (8.5%) and E. coli
Table 1. Commonest microorganisms among 1036 isolates
from patients with bloodstream infections within the ﬁrst
48 h of the index blood culture
Microorganisms No. of isolates %
Escherichia coli 114 11.0
Coagulase-negative staphylococci 112 10.8
Staphylococcus epidermidis 82
Acinetobacter spp. 100 9.6
Streptococci 96 9.3
viridans group 46
Staphylococcus aureus 91 8.8
Enterobacter spp. 84 8.1
Klebsiella spp. 83 8.0
Candida spp.a 81 7.8
Pseudomonas aeruginosa 73 7.0
Enterococci 27 2.6
Enterococcus faecalis 23
Enterococcus faecium 4
Citrobacter spp. 14 1.4
Serratia spp. 10 0.9
Proteus spp. 9 0.8
Flavobacterium spp. 9 0.8
Stenotrophomonas maltophilia 9 0.8
Pseudomonas ﬂuorescens 8 0.7
Chryseobacterium spp. 8 0.7
Alcaligenes spp. 8 0.7
Rhodotorula spp. 7 0.6
Burkholderia cepacia 6 0.5
Corynebacterium spp. 5 0.4
Pseudomonas stutzeri 5 0.4
Bacillus spp. 4 0.3
Pichia ohmeri 3 0.2
Salmonella spp. 3 0.2
Hansenula anomala 3 0.2
Othersb 20 1.9
Unidentiﬁed 44 4.2
aCandida non-albicans 64 (79%): 26 Candida tropicalis, 25 Candida parapsilosis, four
Candida guilliermondii, three each of Candida glabrata and Candida krusei, one each of
Candida kefyr, Candida rugosa and Candida zeylanoides.
bTwo isolates each of Listeria monocytogenes, Cedecae spp., Trichosporum spp.,
Cryptococcus neoformans, Aeromonas spp., Neisseria meningitidis, Rhodococcus equi,
Morganella morganii, Ralstonia pickettii and Haemophilus spp.
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(8.2%). Poly-microbial and uni-microbial BSI epi-
sodes were distributed equally among surgical
and non-surgical patients (28.3% vs. 26.0%;
p 0.62).
One-quarter of the BSIs were in patients with a
£ 30-day history of previous surgery (n ¼ 217;
25.3%). Of these, 25.0% were on mechanical
ventilatory support. Overall, AGNB (58.9% vs.
55.3%, p 0.29), Gram-positive cocci (29.0% vs.
32.4%; p 0.29) and fungi (10.2% vs. 9.9%; p 0.89)
were isolated with equal frequency among surgi-
cal and non-surgical patients. In surgical patients,
the predominant isolates were Enterobacter spp.
(12.9%), CoNS (11.5%), Acinetobacter spp. (10.0%),
Klebsiella spp. (8.2%) and Candida spp. (8.2%).
An indwelling CVC was present in 61.0%
(n ¼ 524) of BSI episodes, and most were long-
term (n ¼ 325; 62.0%). Among patients with
CVCs, there was a higher proportion of AGNB
isolates (n ¼ 325; 50.2%) than Gram-positive
cocci (n ¼ 197; 30.5%; p < 0.01). The comparative
distribution of strains according to CVC type is
shown in Table 3. Gram-negative bacilli (52.7%
vs. 56.9%; p 0.30), Gram-positive cocci (29.6% vs.
31.7%; p 0.57) and fungi (14.3% vs. 10.7%; p 0.18)
were distributed equally in episodes involving
long- and short-term CVCs, respectively. How-
ever, E. coli predominated in patients with long-
term CVCs (9.9% vs. 2.3%; p < 0.01), while
Acinetobacter spp. were associated more fre-
quently with short-term CVCs (15.3% vs. 9.3%;
p 0.02). Of 81 candidaemias, 67 (82.7%) occurred
in patients with a CVC, with equal distribution
according to the type of indwelling CVC (p 0.57).
There was no difference between the propor-
tions of AGNB in patients with haematological
malignancies and solid tumours (56% vs. 56.4%,
respectively). As shown in Table 4, E. coli and
K. pneumoniae were isolated more frequently from
haematology patients (p < 0.05). In contrast, Ente-
robacter spp. were a signiﬁcant cause of bacterae-
mia in solid tumour patients (p 0.05). Viridans
streptococci comprised 54% of streptococci iso-
lates from haematology patients and 56% of
isolates from neutropenic patients.
Neutropenic patients presented with E. coli,
Klebsiella spp. and P. aeruginosa bacteraemia
more frequently than non-neutropenic patients
Table 2. Antibiotic resistance among
the most common Gram-negative
bacteria isolated in the ﬁrst 48 h Microorganisms (no. tested)
Percentage of resistant isolates
AMK CAZ FEP TZP CIP IPM
Escherichia coli (124) 3.6 9.6 9.6 11.8 9.9 0
Acinetobacter baumannii (82)a 32.9 36.6 34.2 18.7 29.5 5.1
Klebsiella pneumoniae (74) 12.3 37.8 37.8 37.8 11.0 0
Pseudomonas aeruginosa (73)b 22.5 23.9 28.2 21.1 32.4 14.1
Enterobacter cloacae (58) 14.3 55.1 15.8 48.2 28.1 0
Enterobacter aerogenes (22) 0 40.9 9.5 33.3 0 0
Acinetobacter lwofﬁi (18)c 22.2 55.5 33.3 33.3 11.2 5.6
AMK, amikacin; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin + tazobactam; CIP, ciproﬂoxacin; IPM,
imipenem.
aOne strain was resistant to all drugs tested.
bFive strains were resistant to all drugs tested, except for polymyxin.
cNo multiresistant strains.
Table 3. Comparative distribution of the commonest
pathogens recovered from blood of patients with long-
and short-term central venous catheters within the ﬁrst
48 h of the bloodstream infection episode
Long-term CVC
n (%)
Short-term CVC
n (%) p
No. of isolates 385 262
Coagulase-negative staphylococci 58 (15.1) 40 (15.3) 0.94
Candida spp. 42 (10.9) 25 (9.5) 0.57
Escherichia coli 38 (9.9) 6 (2.3) < 0.01
Acinetobacter spp. 36 (9.3) 40 (15.3) 0.02
Klebsiella spp. 29 (7.5) 19 (7.3) 0.89
Enterobacter spp. 28 (7.3) 30 (11.5) 0.07
Staphylococcus aureus 24 (6.2) 24 (9.2) 0.16
Streptococci 24 (6.2) 10 (3.8) 0.18
Pseudomonas aeruginosa 10 (2.6) 22 (2.4) 0.80
CVC, central venous catheter.
Table 4. Comparative distribution of the commonest
pathogens recovered from blood of patients with haema-
tological malignancies and solid tumours within the ﬁrst
48 h of the bloodstream infection episode
Haematological
malignancies
n (%)
Solid
tumours
n (%) p
No. of isolates 414 622
Escherichia coli 59 (14.3) 55 (8.8) < 0.01
Klebsiella spp. 43 (10.4) 40 (6.4) 0.02
Coagulase-negative staphylococci 42 (10.1) 70 (8.2) 0.28
Streptococci 37 (8.9) 59 (9.5) 0.76
Staphylococcus aureus 35 (8.5) 56 (9.0) 0.76
Acinetobacter spp. 32 (7.7) 68 (10.9) 0.09
Pseudomonas aeruginosa 29 (7.0) 44 (7.1) 0.97
Candida spp. 29 (7.0) 52 (8.4) 0.43
Enterobacter spp. 25 (6.0) 59 (9.5) 0.05
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(p < 0.05), while Acinetobacter spp. and Enterob-
acter spp. were recovered more frequently from
non-neutropenic patients (p < 0.05) (Table 5).
DISCUSSION
The importance of nosocomial BSI surveillance for
prevention and control of infection, and the
impact of rapid laboratory detection of causative
organisms on clinical outcomes and economic
aspects, has been highlighted previously [13–15].
Streamlining therapy as soon as the susceptibility
pattern of the infectious agent is known will help
to prevent unnecessary use of broad-spectrum
antibiotics and will eventually decrease selection
of resistant organisms.
The continuous prospective BSI surveillance
programme developed in this institution revealed
the magnitude of unnecessary use of antibiotics in
cancer patients. The information obtained is used
to optimise empirical antimicrobial therapy for
febrile neutropenic and non-neutropenic patients,
and also to monitor the trends of aetiological
agents and their resistance patterns. Patients
harbouring carbapenem-resistant AGNB are
immediately placed in isolation. Some reports
evaluating the impact of infectious diseases spe-
cialists on the management of BSI have demon-
strated a reduction in the incidence of serious
medical complications through rapid microbiolo-
gical reporting and further participation in patient
care [14,15]. Although the present study did not
evaluate the effect of surveillance on clinical
outcome, the crude mortality rate observed dur-
ing the current study period, after the develop-
ment of the surveillance programme, was
signiﬁcantly lower than that observed previously
(25.0% vs. 34.0%, respectively; p < 0.01) [8].
The aetiology of BSI in cancer patients has
changed signiﬁcantly. From the mid-1980s, there
was a steady increase in Gram-positive organ-
isms, most notably among neutropenic patients,
from predominantly AGNB in the late 1960s and
early 1970s [16,17]. The present study emphasised
the important role of Gram-positive organisms,
such as CoNS, streptococci and S. aureus, in
cancer patients with BSI, whether they were
neutropenic or not. However, more Gram-negat-
ive bacilli than Gram-positive cocci and fungi
(56.0% vs. 32.0% vs. 10.0%, respectively;
p < 0.01) were observed, in contrast to a previous
study [8] which showed a similar proportion of
AGNB and Gram-positive organisms (45.0% and
42.1%, respectively). The reasons for this change
are unknown, although it is probably a result of
complex interactions involving patients’ underly-
ing conditions, chemotherapeutic regimens, anti-
biotic use, prolonged hospitalisation, and the
quality of care provided.
Critically ill surgical patients, admitted to
intensive care units, are considered to be at higher
risk for BSI than those admitted to other hospital
wards [18]. The prevalence of BSI in patients
admitted for surgical resection of solid tumours
was signiﬁcantly higher than found previously
(25.3% vs. 17.2%; p < 0.01) [8]. This trend can be
explained by the high number of patients on
mechanical ventilatory support and exposed to
invasive procedures after developing severe post-
operative complications. The present study found
59% of surgical patients with Gram-negative
bacteraemia, which is interpreted by some
authors as resulting from device-related infec-
tions or cross-transmission between patients as a
result of poor adherence to infection control
measures [19,20]. The high prevalence of bacter-
aemia caused by Acinetobacter spp. and Enterob-
acter spp. emphasised the increasing importance
of these strains among critically ill non-neutrop-
enic patients [20–22]. Interestingly, 26.8% of these
isolates were from patients with indwelling short-
term CVCs, which may represent secondary
bacterial seeding or inadequate catheter manipu-
lation.
Neutropenic cancer patients frequently have
multiple and recurrent Gram-negative bacterae-
mia secondary to severe and persistent impaired
host defences [23]. Bacteraemia in neutropenic
patients was caused mainly by Enterobacteria-
ceae, P. aeruginosa and streptococci (usually viri-
Table 5. Comparative distribution of the commonest
pathogens recovered from blood of neutropenic and non-
neutropenic patients within the ﬁrst 48 h of the blood-
stream infection episode
Neutropenic
episodes
n (%)
Non-neutropenic
episodes
n (%) p
No. of isolates 341 695
Escherichia coli 55 (16.1) 60 (8.6) < 0.01
Coagulase-negative staphylococci 39 (11.4) 73 (10.6) 0.70
Klebsiella spp. 36 (10.6) 47 (6.8) 0.03
Streptococci 34 (10.0) 62 (8.9) 0.58
Pseudomonas aeruginosa 34 (10.0) 39 (5.6) < 0.01
Candida spp. 28 (8.2) 53 (7.6) 0.74
Staphylococcus aureus 26 (7.6) 65 (9.4) 0.35
Acinetobacter spp. 20 (5.9) 80 (11.5) < 0.01
Enterobacter spp. 12 (3.5) 72 (10.4) < 0.01
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dans group), as found previously [24–26]. Most of
these episodes were uni-microbial and of un-
known origin (27.0%) or catheter-related (23.4%).
Invasive therapeutic interventions and mucosal
lesions breaking down the defence barriers are
among the most common predisposing factors for
BSI. Among these patients with intravascular
catheters of various types, S. aureus and CoNS
continue to be the leading cause of uni-microbial
bacteraemia. The importance of BSI surveillance
to detect trends in infection and the appearance of
resistant strains has been demonstrated in
patients with oncology and haematological malig-
nancies [27]. There was a higher incidence of
AGNB isolates in oncology than in haematology
patients with BSI, although Gram-positive organ-
isms were signiﬁcantly more frequent than AGNB
among haematology patients. However, these
authors observed the emergence of non-fermen-
tative bacilli other than P. aeruginosa as important
aetiological agents of bacteraemia in haematology
patients, which was related to central line infec-
tions. In the present study, there was a statistically
higher incidence of AGNB in patients with a CVC.
The proportion (26.2%) of poly-microbial BSI
had not changed since a previous study [8], and
was similar to that in other reports which iden-
tiﬁed the important association between these
infections and underlying malignancies, immu-
nosuppressive therapy, invasive procedures and
major gastrointestinal operations [28,29]. The
predominance of AGNB in poly-microbial infec-
tions, as found in the present study, has also been
noted previously [30].
Candida spp. are well-established causative
pathogens of nosocomial infections in cancer
patients. In the present study, these strains were
the eighth most commonly recovered BC isolates,
accounting for c. 8% of all BSI. Most (79%) of
these fungal infections were caused by non-
albicans strains, as seen previously [31,32],
although this is a change in this institution from
the predominance (59.4%) of C. albicans in 1993–
1994 [8]. The high proportion of candidaemias in
patients with CVCs suggests that catheters are a
predisposing factor in this high-risk population.
Nevertheless, in contrast to other reports [33,34],
there was no signiﬁcant difference in candidae-
mia occurrence according to neutrophil count or
previous surgical procedures.
Nosocomial bacterial bloodstream isolates fre-
quently demonstrate high levels of resistance
against most tested antibiotics as a result of the
selective pressure of broad-spectrum antibiotics
[35]. This is highlighted by the high degree
of antimicrobial resistance to third-generation
cephalosporins, which are among the most fre-
quently prescribed drugs for critically ill and
cancer patients [11,36–38]. The resistance rates to
ceftazidime for P. aeruginosa (23.9%) and Acine-
tobacter spp. (40.0%) are a cause for concern. Five
(6.8%) isolates of P. aeruginosawere resistant to all
antimicrobial agents tested. In addition, the gen-
era most likely to produce Bush group 1 (Amp C)
b-lactamases (Enterobacter, Citrobacter and Serra-
tia), accounted for 10.4% of all isolates, and 48%
of these were resistant also to ceftazidime.
Furthermore, among E. coli and K. pneumoniae
isolates, the most frequent producers of ESBLs,
ceftazidime resistance reached 20%. This resist-
ance pattern among AGNB leads to an increasing
reliance on carbapenems, highlighting the neces-
sity for surveillance of carbapenem susceptibility.
Although the observed antimicrobial resistance
percentage is higher than that reported in the
SENTRY surveillance programme in Europe [39],
the rates are similar to those of other studies
[28,37] which demonstrated the potential relation-
ship between antecedent antimicrobial drug expo-
sure and length of hospital stay following
selection of resistant organisms in critically ill
and cancer patients. The prevalence (18.7%) of
oxacillin resistance in S. aureus isolates was within
the range of the SENTRY European study. All
Gram-positive cocci remained fully susceptible to
vancomycin.
The present study was designed to assess the
microbiology of BSI in a single cancer centre,
providing data on distribution and in-vitro sus-
ceptibility which can be used for further compar-
ison with other centres. In addition, this
surveillance study underscores the importance
of antimicrobial resistance control through a
careful assessment of the need for and judicious
prescription of adequate antimicrobial therapy in
this high-risk group of patients, indicating which
drugs remain active and which can be used alone
or in combination.
The dissemination of resistant strains occurs
mainly by transmission via the hands of health
care workers, and it has been estimated that
30–40% of endemic institutional antibiotic resist-
ance is caused by poor adherence to hand hygiene
[40]. Therefore, a continuous multidisciplinary
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approach is warranted in order to reinforce
strategies for infection control, which will cer-
tainly play an important role in the prevention
and treatment of these severe infectious compli-
cations.
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